Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Biotechnology

Healthcare
$1.36 +0.83%

+$0.03 today

Market cap
$133.64M
Beta
1.98
P/E (TTM)
-2.1
EPS (TTM)
-$1.77
52W Low $1.13High $6.95

Volume 1.45M

Average 2.00M

Returns on capital

Zentalis Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-63.4%

avg -59.4%

ROIC

-59.6%

avg -54.1%

ROA

-47.4%

avg -43.7%

Analysis

ROA is currently the strongest return metric at -47.4% versus its period average of -43.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Julie Eastland

Chief Executive Officer, President & DirectorUSD 1.14M62——

Ingmar Bruns

Chief Medical OfficerUSD 825.95K5143.06K0.06%

James Bucher

Chief Legal Officer & Corporate SecretaryUSD 556.68K60——

Vincent Vultaggio

SVP of Finance & Principal Accounting Officer—42146.51K0.21%

Rajesh Israni

Executive VP of Regulatory Affairs & Medical Writing————

Robert J. DiVasto

Chief Technical Officer—70——

Henry Gu

Senior Vice President & Head of Intellectual Property————

Sarah Kelly

Senior Vice President of Commercial Strategy————

Haibo Wang

Chief Business Officer————

Wendy Chang

Chief People Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$22.92M

Sells

10

$10.11M

Net Transaction Value

+$12.81M

Net buying

Most Active

Vultaggio Vincent

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 14, 26

WALTERS GROUP

Direct

Buy$15.2M
Feb 10, 26

Vultaggio Vincent

Direct

Sell$16.7K
Feb 9, 26

Vultaggio Vincent

Direct

Sell$8.1K
Feb 9, 26

Bruns Ingmar

Direct

Sell$801.6
Feb 9, 26

EASTLAND JULIA MARIE

Direct

Sell$2.1K
Feb 6, 26

Bruns Ingmar

Direct

Sell$7.2K
Feb 6, 26

EASTLAND JULIA MARIE

Direct

Sell$19.1K
Feb 6, 26

Vultaggio Vincent

Direct

Sell$72.8K
Feb 3, 26

Vultaggio Vincent

Direct

Sell$1.4K
Feb 2, 26

Vultaggio Vincent

Direct

Sell$6.5K

1–10 of 12

Summary

Insiders reported 2 buys worth $22.92M and 10 sells worth $10.11M over the last 12 months. That adds up to net buying of $12.81M. Vultaggio Vincent was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Zentalis Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ZNTL's management, answered from reported figures.

Who manages ZNTL?

Zentalis Pharmaceuticals, Inc. (ZNTL) lists 10 active executives. The top listed executive is Vincent Vultaggio, SVP of Finance & Principal Accounting Officer.

Are ZNTL insiders buying or selling?

Recent insider activity shows net buying of $230.54M.